
AstraZeneca CEO Sir Pascal Soriot Faces Scrutiny Over Potential $400bn Bristol Myers Squibb Merger
AstraZeneca CEO Sir Pascal Soriot, 67, is under scrutiny for a potential $400bn merger with Bristol Myers Squibb, which could jeopardize his legacy and expose the company to debt and patent cliff risks.


















